Abstract

Triarylborane Lewis acids bind [Fe2(pdt)-(CO)4(CN)2]2− (pdt2− = 1,3-propanedithiolate) and [Fe2(adt)(CO)4(CN)2]2− [3]2− (adt2− = 1,3-azadithiolate, HN(CH2S−)2) to give the 2:1 adducts [Fe2(xdt)-(CO)4(CNBAr3)2]2−. Attempts to prepare the 1:1 adducts [1(BAr3)]2− (Ar = Ph, C6F5) were unsuccessful, but related 1:1 adducts were obtained using the bulky borane B(C6F4-o-C6F5)3 (BArF*3). By virtue of the N-protection by the borane, salts of [Fe2(pdt)(CO)4(CNBAr3)2]2− sustain protonation to give hydrides that are stable (in contrast to [H1]−). The hydrides [H1(BAr3)2]− are 2.5–5 pKa units more acidic than the parent [H1]−. The adducts [1(BAr3)2]2− oxidize quasi-reversibly around −0.3 V versus Fc0/+ in contrast to ca. −0.8 V observed for the [1]2−/− couple. A simplified synthesis of [1]2−, [3]2−, and [Fe2(pdt)(CO)5(CN)]− ([2]−) was developed, entailing reaction of the diiron hexacarbonyl complexes with KCN in MeCN.
Introduction
A highlight in the history of bioorganometallic chemistry is the discovery of cyanide ligands as cofactors in the [FeFe] and [NiFe] hydrogenases (H2ases).1 The role of cyanide in H2ases remains underdetermined since few models incorporating this cofactor are available for testing, and those models that do exist exhibit reactions highly complicated by the behavior of the cyanide ligands.2 Hydrogen bonding between the protein backbone and cyanide is known to anchor the active sites, which are otherwise lightly tethered to the protein.3 Cyanide is a powerful σ-donor ligand that in part serves to stabilize the ferrous state, as illustrated by the redox inactivity of the Fe(CN)2(CO) center in the [NiFe] H2ases.4 The situation is different in the [FeFe] H2ases since each Fe center carries one cyanide and at least one of the Fe centers undergoes redox.5
In synthetic analogues, cyanide interferes with the two key attributes of functional models: acid/base and redox reactions. Thus, even though salts of [Fe2(pdt)(CO)4(CN)2]2− (pdt2− = 1,3-propanedithiolate), [1]2−, were described in 1999,6,7 little work has been reported since their initial discovery in part because the products of protonation and oxidation of [1]2− are unstable. Protonation of (Et4N)2[1] occurs initially at the basic Fe–CN followed by formation of the μ-hydrido derivative Et4N[(μ-H)Fe2(pdt)(CO)4(CN)2] (Et4N[H1]), which exists as two major isomers.8,9 The salt Et4N[H1] is labile, with a half-life of minutes in solution. Both chemical and electrochemical studies indicate that oxidized derivatives of [1]2− are unstable.10 As a consequence of the problems associated with cyanide-centered reactions, most functional models feature phosphine ligands as surrogates.11,12
Although cyanide is not compatible with many modeling schemes owing to its ambidentate reactivity, nature prevents such problems by encapsulating the active site in globular proteins. The crystal structures of the [FeFe] H2ases demonstrate the significance of hydrogen bonding to cyanide as observed in the 1.39 Å structure for the CpI enzyme from Clostridium pasteurianum (Figure 1).13 The distal Fe–CN is strongly hydrogen-bonded to the ammonium center of Lys358 (N⋯N distance = 2.74 Å).14 The lysine group is highly conserved, and this specific hydrogen-bonding interaction has been shown to be critical for activity.13,15 The proximal cyanide is also weakly hydrogen bonded to Ser232 (N⋯O distance = 2.92 Å).
Figure 1.

Active site of [FeFe] H2ase (PDB 3C8Y) depicting hydrogen bonding environment to the cyanide ligands.
The present work is premised on the idea that hydrogen bonding to Fe–CN centers can be simulated by FeCN–BR3 interactions. The ability of triarylboranes to bind to cyanide ligands is well-established as exemplified by trans-RuH-(CNBPh3)(diphos)2, Ni(diphos)(π-allyl)(CNBPh3), [M-(CNBArF3)4]2− (M = Ni, Pd; BArF3 = B(C6F5)3), and FeCp(CNBArF3)(CO)2 (diphos = diphosphine).16–18 Moti vated by interest in frustrated Lewis pairs (FLPs)19 and the role of boranes in alkene-polymerization,20 the chemistry of boranes has rapidly developed,21 as have methods to evaluate their Lewis acidities.22 Recently, BArF3 was used to convert the unreactive species (CO)2(CN)2Fe(pdt)Ni(dxpe) (dxpe = dppe, dcpe) into hydride-containing model catalysts capable of catalytic oxidation of H2.23 In parallel with these results, borane Lewis acids were examined with [FeFe]-H2ase active site models, as described below.
Results
Synthesis of [Fe2(pdt)(CO)5(CN)]− and [Fe2(xdt)-(CO)4(CN)2]2− (xdt = adt, pdt)
A new synthesis was developed for cyanide-containing [FeFe]-H2ase models using KCN as a cyanide source (Scheme 1). Quaternary ammonium salts (R4N+, R = Et, Bu) salts of cyanide had previously been used to generate the same anions.6,7 The salt K2[1] formed in good yields upon treating Fe2(pdt)(CO)6 with an excess of KCN in refluxing MeCN. The salt K2[Fe2(adt)(CO)4(CN)2] (adt2− = 1,3-azadithiolate, HN(CH2S−)2) (K2[3]) was prepared analogously, also in good yield. The potassium salts are soluble in MeCN and even dissolve in tetrahydrofuran (THF) and Et2O in the presence of small amounts of MeCN. As we show below, the K+ in these salts usefully modifies the basicity of the Fe–CN centers, allowing the synthesis of complexes unattainable as their Et4N+ salts. The monocyanides K-[Fe2(pdt)(CO)5(CN)] (K[2]) and K[Fe2(adt)(CO)5(CN)] were observed as respective intermediates in the formation of K2[1] and K2[3]. Using a slight deficiency of KCN, K[2] could be prepared in excellent yield from the hexacarbonyl. Like Et4N[2], K[2] exhibits good solubility in MeCN and THF.
Scheme 1.
In the IR spectra of K2[1] and K2[3], the υCO and υCN bands occur at slightly higher energy than the analogous Et4N+ compounds (Table 1).10,24 This shift may be attributed to the coordination of K+ to the cyanide ligands as observed previously for K[CpFe(CO)(CN)2].25 The salt K2[1] was found to undergo anion exchange with PPNCl and Et4NCl in MeCN, shifting υCN and υCO to lower energy, matching the previously reported IR spectrum.6,26
Table 1. IR Bands in the νCN and νCO Regions for Et4N+ and K+ Salts of [1]2−, [2]−, and [3]2−.
| compound | νCN (cm−1) | νCO (cm−1) |
|---|---|---|
| (Et4N)2[1]a | 2075 | 1964, 1924, 1885 |
| K2[1]a | 2077 | 1967, 1928, 1890 |
| Et4N[2]b | 2094 | 2029, 1974, 1955, 1941, 1917 |
| K[2]a | 2092 | 2031, 1976, 1956, 1946, 1916 |
| (Et4N)2[3]a | 2075 | 1969, 1925, 1892 |
| K2[3]a | 2078 | 1969, 1929, 1893 |
MeCN solution.
THF solution, ref 10.
2:1 Borane Adducts of [Fe2(pdt)(CO)4(CN)2]2−
The Lewis acid BArF3 binds to the nitrogen centers of [1]2− to give stable adducts (eq 1)
| (1) |
In addition to BArF3, the weaker Lewis acids BPh3 and B(2,4,6-C6H2F3)3 (BArF#3) also formed related adducts. Treatment of a CH2Cl2 solution of (Et4N)2[1] with 2 equiv of these Lewis acids resulted in lightening of the solution color from red to orange. Upon binding of the borane, IR bands in the υCO and υCN regions shift to higher frequencies (Table 2). On the basis of the υCO bands for the adducts, the relative Lewis acidities of the boranes were BArF3 > BArF#3 > BPh3, as established by Child's methods,22,27,28 computational methods, and other studies.29,30 The coordination of Lewis acids greatly increased the solubility of the complexes. Whereas the uncapped compound (Et4N)2[1] is soluble in MeCN and CH2Cl2, the adducts [1(BAr3)2]2− are soluble in THF and, in the case of [1(BArF 3)2]2−, even in Et2O.
Table 2. IR Bands for (Et4N)2[1(BAr3)2] and Related Complexes in CH2Cl2 Solution.
| compound | νCN (cm−1) | νCO (cm−1) |
|---|---|---|
| (Et4N)2[1] | 2075 | 1964, 1924, 1885 |
| (Et4N)2[1(BPh3)2] | 2137 | 1984, 1946, 1911 |
| (Et4N)2[3(BPh3)2] | 2136 | 1986, 1949, 1914 |
| (Et4N)2[1(BArF#3)2] | 2147 | 1986, 1947, 1915 |
| (Et4N)2[1(BArF 3)2] | 2136 | 1990, 1954, 1922 |
| Fe2(pdt)(CO)4(PMe3)231 | 1979, 1942, 1889 | |
| Fe2(pdt)(CO)4(CNtBu)232 | 2145 | 1997, 1972, 1933 |
Rapid turnstile rotation of Fe(CO)2(CNBAr3) centers was indicated by observation of a single BAr3 environment in the 1H NMR spectra of [1(BPh3)2]2− and [1(BArF#3)2]2−. Similarly, the 19F NMR spectra of [1(BArF#3)2]2− and [1(BArF3)2]2− showed only a single averaged environment. The Fe–CNBAr3 linkage was confirmed by 11B NMR spectra. The 11B NMR spectrum of [1(BArF3)2]2– adducts feature a broadened signal at δ −14. For the alternative linkage isomer Fe–NC–BAr3, a sharp signal is expected near δ −2018. Similarly, the 11B NMR spectrum of [1(BPh3)2]2− exhibits a broad signal at δ −4.5, consistent with a M–CNBPh3− linkage.17 The 11B NMR spectrum of [1(BArF#3)2]2− exhibits a broad signal at δ −15.
The structure of (Et4N)2[1(BArF3)2] was confirmed by X-ray crystallography (Figure 2). Reassuring for our modeling efforts, no obvious structural differences exist between (Et4N)2[1(BArF3)2] and the previously reported structure of (Et4N)2[1]10 (Supporting Information, Table S3). For example, the Fe–Fe, C≡N, Fe–CO, and C≡O distances differ by less than 0.02 Å. Slight shortening of the Fe–CN bond is observed upon coordination of BArF3, with the Fe–CN bond 0.06 Å shorter for (Et4N)2[1(BArF3)2] than for (Et4N)2[1].
Figure 2.

Thermal ellipsoid plot of [1(BArF3)2]2− at 50% probability and with H atoms omitted for clarity. Pentafluorophenyl groups are deemphasized for clarity.
2:1 Borane Adducts of [Fe2(adt)(CO)4(CN)2]2−
Given the basicity of the NH center in [3]2−, adducts of this complex with boranes were anticipated to be more complex than they were for [1]2−. IR measurements indicated that addition of 2 equiv of BArF3 to (Et4N)2[3] resulted in an unstable complex. The less Lewis-acidic BPh3 afforded the desired 2:1 adduct (Et4N)2[Fe2(adt)(CO)4(CNBPh3)2], (Et4N)2[3(BPh3)2]. The IR spectrum of this salt is very similar to that for (Et4N)2[1(BPh3)2] (Table 2). Its 1H NMR spectrum displayed a single BPh3 environment, consistent with both BPh3 groups being bound to Fe-CN centers and rapid rotation of the Fe(CO)2(CNBPh3) subunits.
1:1 Borane Adducts of [Fe2(pdt)(CO)4(CN)2]2−
Attempts were made to generate the 1:1 borane adducts of [1]2−. As indicated by IR spectroscopy, treatment of (Et4N)2[1] with 1 equiv of BArF3 or BPh3 gave a mixture of (Et4N)2[1(BAr3)2], starting material, and insoluble solids (that do not redissolve in the presence of boranes). In an effort to stabilize 1:1 adducts, the bulky borane B(C6F4-o-C6F5)3 (BArF*3) was examined. The reaction of (Et4N)2[1] with 1 equiv of BArF*3 precipitated intractable solids, even when the addition was conducted slowly and on dilute solutions. When 2 equiv of BArF*3 were added quickly, the 2:1 adduct (Et4N)2[1(BArF*3)2] formed in good yield.
The formation of 1:1 adducts required starting with K2[1] instead of the Et4N+ salt. Treatment of K2[1] with 1 equiv of BArF*3 gave K2[1(BArF*3)] (eq 2).
| (2) |
The IR spectrum of this adduct shows υCN bands at disparate energies (2126, 2058 cm−1), consistent with the coordination of BArF*3 to a single cyanide ligand (see Figure 3).
Figure 3.

IR spectra of K2[1] in MeCN (top), K2[1(BArF*3)] in CH2Cl2 (middle), and K2[1(BArF*3)2] in CH2Cl2 (bottom).
The salt K2[1(BArF*3)2] was produced in good yield. This pale red solid exhibits good solubility in ether and THF, as found for (Et4N)2[1(BArF3)2]. The IR spectra of K2[1(BArF*3)] and K2[1(BArF*3)2] were found to vary with solvent (CH2Cl2 vs MeCN). The solvent effect is reversible. In contrast, the IR spectrum for (Et4N)2[1(BArF*3)2] was unchanged in these solvents (Table 3).
Table 3. IR Bands for K2[1] and (Et4N)2[1] and Their BArF*3 Adducts.
| compound | solvent | νCN (cm−1) | νCO (cm−1) |
|---|---|---|---|
| (Et4N)2[1] | MeCN | 2075 | 1964, 1924, 1885 |
| K2[1] | MeCN | 2077 | 1967, 1928, 1890 |
| K2[1(BArF*3)] | MeCN | 2096, 2081 | 1990, 1978, 1942, 1931, 1913, 1888 |
| K2[1(BArF*3)] | CH2Cl2 | 2126, 2058 | 1985, 1950, 1905 |
| K2[1(BArF*3)2] | MeCN | 2098 | 1991, 1959, 1947, 1932, 1910 |
| K2[1(BArF*3)2] | CH2Cl2 | 2119 | 1989, 1951, 1916 |
| (Et4N)2[1(BArF*3)2] | MeCN | 2098 | 1991, 1932 |
| (Et4N)2[1(BArF*3)2] | CH2Cl2 | 2100 | 1990, 1928 |
Hydride Derivatives [(μ-H)Fe2(xdt)(CO)4(CNBAr3)2]− (xdt = adt, pdt)
In contrast to the complications reported for the protonation of [1]2−,9 protonation of the borane adducts [1(BAr3)2]2− proceeded straightforwardly (eq 3).
| (3) |
Exploiting their distinctive solubility, the borane complexes (Et4N)2[1(BAr3)2] were protonated as an ether or THF solution with excess HCl·Et2O. Protonation is accompanied by a lightening in the solution color and precipitation of Et4NCl. Protonation causes a shift of both υCO and υCN to higher energies, consistent with oxidation of the diiron centers (Table 4).
Table 4. IR Bands in ν CN and ν CO Regions for Et4N[H1(BAr3)2] and Related Complexes.
| compound | solvent | νCN (cm−1) | νCO (cm−1) |
|---|---|---|---|
| Et4N[H1] | MeCN | 2118, 2112 | 2045, 2024, 1985 |
| Et4N[H1(BPh3)2] | CH2Cl2 | 2180 | 2064, 2043, 2009 |
| Et4N[H1(BArF#3)2] | CH2Cl2 | 2194 | 2066, 2046, 2012 |
| Et4N[H1(BArF3)2] | CH2Cl2 | 2185 | 2071, 2051, 2022 |
| [(μ-H)Fe2(pdt)(CO)4(PMe3)2]BF4 31 | CH2Cl2 | 2029, 1989 | |
| [([(μ-H)Fe2(pdt)(CO)4(CNtBu)2]BF432 | CH2Cl2 | 2187 | 2076, 2060, 2028 |
The hydrido complexes exhibit characteristic high-field 1H NMR signals. 1H NMR spectra of [H1(BAr3)2]− in CD2Cl2 solution display two or three hydride signals, depending on the borane. Ignoring the conformation of the Fe2pdt center, four isomers are possible for [H1(BAr3)2]−, three of which are symmetrical with equivalent CNBAr3− ligands (Figure 4). All four isomers are observed for the [(μ-H)Fe2(pdt)-(CO)4(CNtBu)2]+ system.32
Figure 4.

Isomers of [H1(BAr3)2]−. Only for the a/b isomer are the CNBAr3− ligands nonequivalent.
Freshly generated solutions of [H1(BArF3)2]− consist of three isomeric hydrides, indicated by 1H NMR signals at δ −13.7, −16.4, and −19.0 in a ratio of 1:11:5. Over the course of 2 d, the isomer ratio shifted to 1:36:32. The structures of these isomers can be partially inferred from the 19F NMR spectra, since the p-F signals are well-resolved. On the basis of these data, the 1H NMR signal at δ −16, which corresponds to the kinetically favored species, is assigned to the unsymmetrical apical/basal (a/b) isomer. The other two hydride signals arise from symmetrical complexes (single 19F NMR signals), probably the b/b and a/a isomers.
The 1H NMR spectrum of [H1(BArF#3)2]− consisted of only two high-field signals, at δ −16.4 and −19.2, in a 3:1 ratio. After equilibration over the course of 3 d, this ratio shifted to 1:1.5. In the 19F NMR spectrum of [H1(BArF#3)2]−, the ratio of the o-F and p-F signals compared to the ratio of the hydride signals are consistent with one symmetric and one asymmetric isomer (Supporting Information). The species with the 1H NMR signal at δ −16.4 is assigned to the a/b isomer on the basis of the relative intensities of 1H and 19F NMR signals.
Freshly generated solutions of [H1(BPh3)2]− consisted of three isomers, indicated by 1H NMR signals at δ −13.3, −16.1, and −19.2 in a ratio of 1.6:4.3:1. This mixture isomerizes over the course of 2 d to a 1:11:11 ratio. The 1H NMR spectrum of [H1(BPh3)2]− features four signals assigned to the 2,6-protons on BPh3, the ratio of which are consistent with two symmetric isomers and one asymmetric isomer. On the basis of the integrations of the hydride signals and ortho-aryl signals of [H1(BPh3)2]−, the high-field signal at δ −16.14 could be assigned as the a/b isomer. The 1H NMR signals for the symmetrical isomers of [H1(BAr3)2]− are assigned in analogy to the assignments for [(μ-H)Fe2(pdt)(CO)4(CNtBu)2]+:32 The most downfield hydride signal (δ −13.5) is assigned to one of the b/b isomers, presumably trans for electrostatic reasons, and the most upfield hydride signal (δ −19.0) is assigned to the a/a isomer.
The boranes noticeably affect the basicity of the diiron unit. The pKaMeCN of [H1]− is estimated to be 16 as it is fully deprotonated by 1 equiv of benzylamine (pKaMeCN = 16.91).33 Protonation of [1]2− to give [H1]− occurs with one equiv 2,4,6-trimethylpyridinium (pKaMeCN = 14.98).33 As observed with [H1]−, both [H1(BArF3)2]− and [H1(BArF#3)2]− can also be reversibly deprotonated. By 19F NMR spectroscopy using anilinium (pKaMeCN = 10.62) as the acid,33 the pKaMeCN of [H1(BArF3)2]− was calculated to be 10.8 ± 0.2. Examination of mixtures of [1(BArF#3)2]2− and pyridinium (pKaMeCN = 12.53)33 gave a pKaMeCN of 13.5 ± 0.1. Deprotonation of [H1(BPh3)2]− with pyridine did not cleanly reform [1(BPh3)2]2−, probably because the adducts of this less-acidic borane are labile. The values for υCO are similar for [H1(BArF#3)2]− and [H1(BPh3)2]−, suggesting that their pKa values are probably comparable. The hydridic nature of [H1(BArF#3)2]− was investigated by treatment of a CD2Cl2 solution of [H1(BArF3)2]− with Me3NHBAr. 1H NMR analysis failed to indicate any interaction.
The presence of adt2− in [FeFe]-H2ase models has been shown to greatly affect the protonation pathway. The protonation of (Et4N)2[3] has been previously reported as occurring at the amine, forming [Fe2(Hadt)(CO)4(CN)2]−, [α-H3]−, followed by slow proton transfer over days to form the unstable bridging hydride [(μ-H)Fe2(adt)(CO)4(CN)2]−, [H3]−.34 Unlike the straightforward protonation of [1(BAr3)2]2−, protonation of [3(BPh3)2]2− proved complicated and sensitive to solvent. Using H(Et2O)2B(ArF6)4 protonation in MeCN solution resulted in N-protonation (ΔυCN ≈ 10 cm−1, ΔυCO ≈ 20 cm−1), whereas protonation in a CH2Cl2 solution produced some bridging hydrides (δ −15.3 and δ−18.4) (ArF6 = C6H3-3,5-(CF3)2, Supporting Information).
Electrochemistry of [Fe2(pdt)(CO)4(CNBAr3)2]2− and [(μ-H)Fe2(pdt)(CO)4(CNBAr3)2]−
According to its cyclic voltammogram, a freshly prepared CH2Cl2 solution of (Et4N)2[1] irreversibly oxidizes at −0.79 V (Figure 5, all potentials vs Fc0/+). The process is accompanied by the appearance of a deposit on the working electrode. In contrast, (Et4N)2[1(BAr3)2] was found to oxidize quasi-reversibly without fouling the electrodes. The oxidation potentials vary between −0.23 and −0.36 V depending on the Lewis acid (Table 5).
Figure 5.

Cyclic voltammograms of (Et4N)2[1] and (Et4N)2[1(BArF3)2] (1 mM solutions in CH2Cl2) with 100 mM Bu4NPF6 as electrolyte recorded at 0.1 V/s.
Table 5. Redox Potentials (V) and Current Ratios of Adducts of [1(BAr3)2]2– and [H1(BAr3)2]– in CH2Cl2 vs Fc0/+ (Scan Rate v = 0.1 V/s).
| BAr3 | E1/2 [1(BAr3)2]2−/− | ipa/ipc | E1/2 [H1(BAr3)2]−/2− | ipc/ipa | E1/2[H1(BAr3)2] | ipa/ipc |
|---|---|---|---|---|---|---|
| none | −0.79 | irrev. | ||||
| BPh3 | −0.36 | 0.16 | −1.72 | irrev. (0.20)a | ||
| BArF#3 | −0.34 | 0.69 | −1.76 | 0.21 (0.44)a | 1.11 | 0.76 |
| BArF3 | −0.23 | 0.82 | −1.65 | 0.28 (0.51)a | 1.24 | 0.57 |
ν = 1.0 V/s.
The redox properties of Et4N[H1] have not been evaluated because of the compound's instability. Borane-capping allowed for the observation of a quasi-reversible reduction for Et4N[H1(BArF3)2] at −1.65 V vs Fc0/+. The potentials of the [1(BAr3)2]2−/− and [H1(BAr3)2]−/2− couples correlated with the Lewis acidity of the borane (Table 5). Reduction of [H1(BPh3)2]− and [H1(BArF#3)2]− occurred near −1.74 V; however, reversibility was only observed at scan rates above 0.5 V/s. Interestingly, BPh3 and BArF#3 had similar effects on the redox potentials even though their Lewis acidities are quite different.28,29,35
Discussion
A new synthesis of [1]2− and [3]2− was developed involving the use of KCN. The method offers advantages over the traditional route: not only is KCN cheaper and safer to use than Et4NCN, it is commercially available in isotopically labeled forms. Once isolated, K2[1] undergoes anion exchange to afford the corresponding Et4N+ and PPN+ salts. In contrast to the use of Et4NCN, substitution using KCN proceeds via the readily isolated intermediate K[Fe2(xdt)(CO)5(CN)].
The coordination of the boranes to [1]2− and [3]2− suppresses reactions at the Fe–CN sites, which complicated previous studies on the protonation and redox of these very appealing models. Capping the Fe–CN sites with boranes allowed for straightforward protonation of [1(BAr3)2]2− to give the μ-hydrido derivatives [H1(BAr3)2]−. Unlike [H1]−, [H1(BAr3)2]− was readily isolated and handled. In solution, [H1(BAr3)2]− exists as a mixture of isomers, the distribution of which is similar for [(μ-H)Fe2(pdt)(CO)4(CNtBu)2]+.32
Dihydrogen bonds between a metal hydrides and a protic group is a key interaction in the evolution and oxidation of hydrogen by H2ases. “Hydridic hydrides” are expected to form dihydrogen bonds with acids.36 Indeed, crystallographic study of the [FeFe]-H2ase model [HFe2(Hadt)(CO)2(dppv)2]2+, which contains both an N-protonated adt and terminal iron hydride, reveals a short NH···HFe distance of 1.8 Å (dppv = cis-C2H2(PPh2)2).12 Similarly, NMR measurements indicate intermolecular dihydrogen bonding between [(CO)-(CNBArF3)2Fe(H)(pdt)Ni(dppe)]− and Me3NH+.23 In contrast, we show in this work that the bridging hydride in [FeFe]-H2ase models do not engage in intramolecular hydrogen bonding.37 Underscoring the nonhydridic nature of FeII(μ-H)FeII species, we observed no interaction between [H1(BAr3)2]− and Me3NH+, despite an electrostatic driving force.
The strengths of the hydrogen bonds from the protein to the two CN− cofactors differ, as reflected by the distances between hydrogen-bonded heteroatoms. The Fedistal –CN⋯N (lysine ε-ammonium) distance is 2.74 Å, whereas the Feproximal – CN⋯O (serine hydroxyl) distance is 2.92 Å.13 To simulate the disparate nature of these two hydrogen-bonding interactions, attempts were made to bind 1 equiv of a Lewis acid to [1]2−. The reaction of 1 equiv of BArF3 and BArF*3 with (Et4N)2[1] gave intractable products. The targeted asymmetrically protected dicyanide complex was obtained by combining the bulky borane BArF*3 and K2[1]. We propose that this adduct is stabilized by binding of K+ to the uncapped FeCN center. This interaction is consistent with the solvent dependence of the IR spectra of K2[1(BArF*3)] and K2[1(BArF*3)2]. In CH2Cl2 solutions, BArF*3 coordinates strongly to Fe–CN, whereas in MeCN solutions K+ appears to compete with BArF*3 for coordination to Fe–CN. The IR spectrum of (Et4N)2[1(BArF*3)2] was found not to vary with solvent.
In terms of ligand properties, how does CNBArF3− compare with related ligands? The answer depends on the method of measurement. Using the criterion of υCO, CNBAr3− is less basic than PMe3.31 Similar ranking is indicated when comparing the pKaMeCN of the corresponding hydrido complexes.38 On the other hand, in terms of redox properties, the [H1 (BAr3)2]2−/− couple (ca. −1.7 V vs Fc0/+) is far more cathodic than the couple [HFe2(pdt)(CO)4(PMe3)2]+/0 (−1.39 V).39
Now that adt2− has been established as the dithiolate cofactor, the question remains: what steps are required to convert [Fe2(adt)(CO)4(CN)2]2− and [(μ-H)Fe2(adt)-(CO)4(CN)2]− into functioning catalysts? Previously the barrier to this activation was the interfering reactivity of the cyanide ligands, which are both bases and potentially bridging ligands. This distracting behavior has been addressed with the introduction of the borane protecting groups, yet the diferrous hydride remains bridging. One obvious gap is the absence of the 4Fe–4S cluster–ligand on the proximal Fe center. Beyond that omission, the rotated structure may require a more protein-like environment, especially a hydrogen-bonding interaction directed at a basal cyanide on the distal Fe. 3,4
Experimental Section
Materials and Methods
Standard Schlenk or glovebox techniques were used. Solvents used for syntheses were high-performance liquid chromatography grade, further purified by using an alumina filtration system (Glass Contour Co., Irvine, CA), and were deoxygenated prior to use. NMR solvents were purchased from Cambridge Isotope Laboratories, dried with CaH2, and stored under nitrogen over activated molecular sieves. The preparations of (Et4N)2[1] and (Et4N)2[3] are described elsewhere.24,42 BArF3 was purchased from Boulder Scientific and twice sublimed under vacuum at 90 °C prior to use. BPh3 was prepared by pyrolysis of HNMe3BPh4.43 The preparations of BArF*3 and BArF3 have been reported. IR spectra were recorded using a PerkinElmer Spectrum 100 FT-IR instrument using a CaF2 solution cell. These data are reported in cm−1. Elemental analyses were conducted at the University of Illinois Microanalysis Laboratory. Cyclic voltammetry was performed under nitrogen at room temperature using a CHI 630D potentiostat with glassy carbon working electrode, Pt wire counter electrode, pseudoreference electrode Ag wire, and with ferrocene as an internal standard. NMR spectra were recorded on a Varian Mercury 500 MHz spectrometer, and the 1H NMR chemical shifts were referenced to the residual protons of deuterated solvents. 11B (recorded on a Varian 400 MHz instrument) and 19F NMR spectra were referenced to external standards of BF3·Et2O and 1% CFCl3 in CDCl3, respectively.
K2[Fe2(pdt)(CO)4(CN)2], K2[1]
A Schlenk flask was charged with Fe2(pdt)(CO)6 (1.0 g, 2.6 mmol), KCN (0.51 g, 7.8 mmol), and MeCN (100 mL). The mixture was heated at reflux for 28 h, with monitoring by IR spectroscopy. The mixture was filtered through Celite, and the filtrate was evaporated under vacuum. The resulting solid was washed with Et2O (50 mL) and hexanes (50 mL) and then dried under vacuum. Yield: 0.91 g (76%). Anal. Calcd for C9H6Fe2K2N2O4S2·0.33CH3CN (found): C, 24.49 (24.35); H, 1.49 (1.64); N, 6.81 (6.88). IR (MeCN): 2077, 1967, 1928, 1890.
K[Fe2(pdt)(CO)5(CN)], K[2]
A two-necked Schlenk flask was charged with Fe2(pdt)(CO)6 (0.50 g, 1.30 mmol), 0.9 equiv of KCN (0.076 g, 1.17 mmol), and MeCN (50 mL). The mixture was heated at reflux for 6 h, with monitoring by IR spectroscopy. The mixture was filtered through Celite, and the filtrate was dried under vacuum. The resulting oil was extracted into Et2O, and product was precipitated with pentane. The resulting solid was collected by filtration, washed with pentane (50 mL), and dried under vacuum. Yield: 0.42 g (85%). Anal. Calcd for C9H6Fe2KNO5S2 (found): C, 25.55 (25.62); H, 1.43 (1.71); N, 3.31 (3.17). IR (MeCN): 2092, 2031, 1976, 1956, 1946, 1916.
(Et4N)2[Fe2(pdt)(CO)4(CNBArF3)2], (Et4N)2[1(BArF3)2]
A slurry of (Et4N)2[l] (2.40 g, 3.74 mmol) in CH2Cl2 (50 mL) was treated with BAr 3 (3.88 g, 7.57 mmol) in CH2Cl2 (10 mL). After stirring the reaction solution for 30 min, the solvent was evaporated to yield a red oil, which a red powder upon standing under vacuum. The product was triturated with pentane (3 × 10 mL) and crystallized from CH2Cl2 (10 mL) layered with Et2O (10 mL) and pentane (30 mL). Yield: 5.25 g (99%). Anal. Calcd for C61B2Fe2S2H46O4N4F30 (found): C, 43.97 (43.50); H, 2.78(3.07); N, 3.36 (3.60). IR (CH2Cl2): 2136, 1990, 1954, 1922. 1H NMR (CD2Cl2): δ 3.10 (16 H, m, (CH3CH2)4N), 1.73 (4 H, t, SCH2CH2CH2S), 1.48 (2 H, m, SCH2CH2CH2), 1.23 (24 H, t, (CH3CH2)4N). 11B NMR (CD2Cl2): δ −14. 19F NMR (CD2Cl2): δ −134 (d, o-F), −162 (t, p-F), −167 (t, m-F). Crystals suitable for X-ray diffraction were obtained by the slow diffusion of pentane into a THF solution of (Et4N)2[l(BArF3)2] at −30 °C.
(Et4N)2[Fe2(pdt)(CO)4(CNBArF#3)2], (Et4N)2[1(BArF#3)2]
A solution of (Et4N)2[1] (0.16 g, 0.25 mmol) in CH2Cl2 (10 mL) was treated dropwise with a solution of BArF#3 (0.20 g, 0.50 mmol) in 10 mL of CH2Cl2. The solvent was evaporated to yield a red oil, which was extracted into CH2Cl2 (5 mL). The extract was layered with pentane (20 mL) and cooled at −30 °C for 2 d, producing a red oil. The filtrate was decanted off, and the oil was triturated with pentane (3 × 10 mL) to produce a red solid. Yield: 0.34 g (95%). Anal. Calcd for C61H58B2F18Fe2N4O4S2 (found): C, 50.51 (50.82); H, 4.03 (4.04); N, 3.86 (4.15). IR (CH2Cl2): 2147, 1986, 1947, 1915. 1H NMR (CD2Cl2): δ 6.41 (12 H, t, m-ArH), 3.09 (16H, m, (CH3CH2)4N), 1.70 (4 H, t, SCH2CH2CH2S), 1.42 (2 H, m, SCH2CH2CH2), 1.22 (24 H, t, (CH3CH2)4N). 11B NMR (CD2Cl2): δ −15. 19F NMR (CD2Cl2): δ −99.9 (s, o-F), −117.1 (s, p-F).
K2[Fe2(pdt)(CO)4(CN)(CNBArF*3)], K2[1(BArF*3)]
A solution of K2[1] (26 mg, 0.058 mmol) in MeCN (20 mL) was treated over the course of 2 h dropwise with a MeCN solution (10 mL) of BArF*3 (50 mg, 0.052 mmol). The solvent was then removed under vacuum and the residue was extracted into 5 mL of Et2O. The extract was passed through Celite and then evaporated under vacuum to yield a tacky red solid, which was triturated with pentane (3 × 10 mL). Yield: 50 mg (68%). Anal. Calcd for C45BFe2S2H6O4N2F27K2·0.33CH3CN· OEt2 (found): C, 39.66 (40.03); H, 1.14 (0.88); N, 2.17 (2.03). IR (MeCN): 2096, 2081, 1990, 1978, 1942, 1931, 1913, 1888. IR (CH2Cl2): 2100, 1990, 1927.
K2[Fe2(pdt)(CO)4(CNBArF*3)2], K2[1(BArF*3)2]
A solution of K2[1] (24 mg, 0.052 mmol) in MeCN (5 mL) was treated with a solution of BArF*3 (100 mg, 0.11 mmol) in MeCN (10 mL). The solvent was then removed under vacuum. The residue was extracted into 5 mL of Et2O, and this extract was treated with 20 mL of pentane, precipitating a red oil that was triturated with pentane (3 × 10 mL) to yield a red solid. Yield: 84 mg (68%). IR (MeCN) 2098, 1991, 1959, 1947, 1932, 1909. IR (CH2Cl2): 2119, 1989, 1951, 1916.
Et4N[(μ-H)Fe2(pdt)(CO)4(CNBArF3)2], Et4N[H1(BArF3)2]
A solution of (Et4N)2[1(BArDF3)2] (0.282 g, 0.169 mmol) in ether (50 mL) was treated with HCl in ether (0.093 mL, 2 M, 0.186 mmol). The reaction solution color became lighter, and a colorless precipitate formed. The reaction solution was stirred for 30 min and was filtered through a plug of Celite to remove Et4NCl. The filtrate was collected, the solvent was evaporated to ca. 10 mL, and pentane (20 mL) was added. The resulting red solid was extracted into ether (10 mL), and this extract was layered with pentane (30 mL) to yield yellow microcrystals. Yield: 107 mg (44%). Anal. Calcd for C53B2Fe2S2H27O4N3F30 (found): C, 41.41 (41.29); H, 1.77 (1.75); N, 2.73 (2.66). IR (CH2Cl2): 2185, 2071, 2051, 2022. 1H NMR (CD2Cl2): δ −13.7 (s, Fe-H), −16.4 (s, Fe-H), −19.0 (s, Fe-H). 19F NMR (CD2Cl2): δ −134.8 (dd, o-F), −134.9 (m, o-F), −160.4 (t, p-F), −160.8 (t, p-F), −160.9 (t, p-F),−166.2 (m, m-F), -166.5 (td, m-F), −166.6 (td, m-F). 11B NMR (CD2CL2): δ −15.
Et4N[i-H)Fe2(pdt)(CO)4(CNBArF#3)2], Et4N[H1(BArF#3)2]
A solution of (Et4N)2[1(BArF#3)2] (100 mg, 0.069 mmol) in THF (1 mL) was treated with a solution of HCl in ether (0.1 mL, 2M, 0.2 mmol), resulting in the color of the solution lightening and the appearance of some solid precipitate. The reaction solution was cooled to -30 °C to precipitate Et4NCl and was then filtered through a plug of Celite. The solution was evaporated under vacuum, and the resulting oil was triturated with pentane (3 × 10 mL) and left to dry under vacuum overnight, yielding a red solid. Yield: 91 mg (99%). Anal. Calcd for C53H39B2F18Fe2N3O4S2 (found): C, 48.18 (48.51); H, 2.97 (3.17); N, 3.18 (3.16). IR (CH2Cl2): 2194, 2066, 2046, 2012. 1H NMR (CD2Cl2): δ −16.41 (s, Fe-H), −19.16 (s, Fe-H). 19F NMR (CD2Cl2): δ −100.6 (s, o-F), −100.8 (s, o-F), -116.1 (s, p-F), −116.3 (s, p-F).
pKa Determinations
Solutions of (Et4N)2[1(BArF3)2] and Ph3NHBArF24·2Et2O or (Et4N)2[1(BArF#3)2] and PyHBArF24 were prepared in MeCN with approximate [l(BAr3)2]2− /acid ratios of 1:2, 1:1, and 2:1 and examined by 19F NMR spectroscopy. Solutions reached equilibrium at room temperature over 24 h. The pKa was then determined using the Henderson–Hasselbach equation.
Supplementary Material
Acknowledgments
This research was supported by the U.S. National Institutes of Health and the International Institute for Carbon Neutral Energy Research (WPI-I2CNER), sponsored by the World Premier International Research Center Initiative (WPI), MEXT, Japan. We thank Dr. D. Gray for assistance with the crystallography.
Footnotes
Supporting Information: Synthetic procedures, IR and NMR spectra, cyclic voltammo-grams, and .cif files. This material iavailable free of charge via the Internet at http://pubs.acs.org.
Notes: The authors declare no competing financial interest.
References
- 1.(a) Pierik AJ, Hulstein M, Hagen WR, Albracht SPJ. Eur J Biochem. 1998;258:572. doi: 10.1046/j.1432-1327.1998.2580572.x. [DOI] [PubMed] [Google Scholar]; (b) Pierik AJ, Roseboom W, Happe RP, Bagley KA, Albracht SPJ. J Biol Chem. 1999;274:3331. doi: 10.1074/jbc.274.6.3331. [DOI] [PubMed] [Google Scholar]
- 2.Tard C, Pickett C. J Chem Rev. 2009;109:2245. doi: 10.1021/cr800542q. [DOI] [PubMed] [Google Scholar]
- 3.Knorzer P, Silakov A, Foster CE, Armstrong FA, Lubitz W, Happe T. J Biol Chem. 2012;287:1489. doi: 10.1074/jbc.M111.305797. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Ogata H, Lubitz W, Higuchi Y. Dalton Trans. 2009:7577. doi: 10.1039/b903840j. [DOI] [PubMed] [Google Scholar]
- 5.Mulder DW, Ratzloff MW, Shepard EM, Byer AS, Noone SM, Peters JW, Broderick JB, King PW. J Am Chem Soc. 2013;135:6921. doi: 10.1021/ja4000257. [DOI] [PubMed] [Google Scholar]
- 6.Schmidt M, Contakes SM, Rauchfuss TB. J Am Chem Soc. 1999;121:9736. [Google Scholar]
- 7.Lyon EJ, Georgakaki IP, Reibenspies JH, Darensbourg MY. Angew Chem, Int Ed. 1999;38:3178. [PubMed] [Google Scholar]; Le Cloirec A, Best SP, Borg S, Davies SC, Evans DJ, Hughes DL, Pickett C. J Chem Commun. 1999:2285. [Google Scholar]
- 8.Jablonskytė A, Wright JA, Pickett CJ. Dalton Trans. 2010;39:3026. doi: 10.1039/b923191a. [DOI] [PubMed] [Google Scholar]
- 9.Zhao X, Georgakaki IP, Miller ML, Yarbrough JC, Darensbourg MY. J Am Chem Soc. 2001;123:9710. doi: 10.1021/ja0167046. [DOI] [PubMed] [Google Scholar]
- 10.Gloaguen F, Lawrence JD, Schmidt M, Wilson SR, Rauchfuss TB. J Am Chem Soc. 2001;123:12518. doi: 10.1021/ja016071v. [DOI] [PubMed] [Google Scholar]
- 11.Camara JM, Rauchfuss TB. Nat Chem. 2012;4:26. doi: 10.1038/nchem.1180. [DOI] [PMC free article] [PubMed] [Google Scholar]; Zaffaroni R, Rauchfuss TB, Gray DL, De Gioia L, Zampella G. J Am Chem Soc. 2012;134:19260. doi: 10.1021/ja3094394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Carroll ME, Barton BE, Rauchfuss TB, Carroll PJ. J Am Chem Soc. 2012;134:18843. doi: 10.1021/ja309216v. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Pandey AS, Harris TV, Giles LJ, Peters JW, Szilagyi RK. J Am Chem Soc. 2008;130:4533. doi: 10.1021/ja711187e. [DOI] [PubMed] [Google Scholar]
- 14.Greco C, Bruschi M, Heimdal J, Fantucci P, De Gioia L, Ryde U. Inorg Chem. 2007;46:7256. doi: 10.1021/ic701051h. [DOI] [PubMed] [Google Scholar]
- 15.Fourmond V, Greco C, Sybirna K, Baffert C, Wang PH, Ezanno P, Montefiori M, Bruschi M, Meynial-Salles I, Soucaille P, Blumberger J, Bottin H, De Gioia L, Léger C. Nat Chem. 2014;6:336. doi: 10.1038/nchem.1892. [DOI] [PubMed] [Google Scholar]
- 16.Rocchini E, Rigo P, Mezzetti A, Stephan T, Morris RH, Lough AJ, Forde CE, Fong TP, Drouin SD. J Chem Soc, Dalton Trans. 2000:3591. [Google Scholar]; Zhou JM, Lancaster SJ, Walker DA, Beck S, Thornton-Pett M, Bochmann M. J Am Chem Soc. 2001;123:223. doi: 10.1021/ja002820h. [DOI] [PubMed] [Google Scholar]
- 17.Brunkan NM, Brestensky DM, Jones WD. J Am Chem Soc. 2004;126:3627. doi: 10.1021/ja037002e. [DOI] [PubMed] [Google Scholar]
- 18.Vei IC, Pascu SI, Green MLH, Green JC, Schilling RE, Anderson GDW, Rees LH. Dalton Trans. 2003:2550. [Google Scholar]
- 19.Stephan DW, Erker G. Angew Chem, Int Ed. 2010;49:46. doi: 10.1002/anie.200903708. [DOI] [PubMed] [Google Scholar]
- 20.Luo L, Marks TJ. Top Catal. 1999;7:97. [Google Scholar]
- 21.(a) Erker G. Dalton Trans. 2005:1883. doi: 10.1039/b503688g. [DOI] [PubMed] [Google Scholar]; (b) Piers WE. Adv Organomet Chem. 2005;52:1. [Google Scholar]
- 22.Britovsek GJP, Ugolotti J, White AJP. Organometallics. 2005;24:1685. [Google Scholar]
- 23.Manor BC, Rauchfuss TB. J Am Chem Soc. 2013;135:11895. doi: 10.1021/ja404580r. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Lawrence JD, Li HX, Rauchfuss TB, Benard M, Rohmer MM. Angew Chem, Int Ed. 2001;40:1768. doi: 10.1002/1521-3773(20010504)40:9<1768::aid-anie17680>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
- 25.(a) Coffey CE. J Inorg Nucl Chem. 1963;25:179. [Google Scholar]; (b) Darensbourg DJ, Reibenspies JH, Lai CH, Lee WZ, Darensbourg MY. J Am Chem Soc. 1997;119:7903. [Google Scholar]
- 26.Boyer JL, Rauchfuss TB, Wilson SR. C R Chim. 2008;11:922. [Google Scholar]
- 27.(a) Morrison DJ, Piers WE. Org Lett. 2003;5:2857. doi: 10.1021/ol034928i. [DOI] [PubMed] [Google Scholar]; (b) Welch GC, Cabrera L, Chase PA, Hollink E, Masuda JD, Wei PR, Stephan DW. Dalton Trans. 2007:3407. doi: 10.1039/b704417h. [DOI] [PubMed] [Google Scholar]
- 28.Nicasio JA, Steinberg S, Ines B, Alcarazo M. Chem—Eur J. 2013;19:11016. doi: 10.1002/chem.201301158. [DOI] [PubMed] [Google Scholar]
- 29.Durfey BL, Gilbert TM. Inorg Chem. 2011;50:7871. doi: 10.1021/ic201182p. [DOI] [PubMed] [Google Scholar]
- 30.Chakraborty D, Rodriguez A, Chen EYX. Macromolecules. 2003;36:5470. [Google Scholar]
- 31.Zhao X, Georgakaki IP, Miller ML, Mejia-Rodriguez R, Chiang CY, Darensbourg MY. Inorg Chem. 2002;41:3917. doi: 10.1021/ic020237r. [DOI] [PubMed] [Google Scholar]
- 32.Nehring JL, Heinekey DM. Inorg Chem. 2003;42:4288. doi: 10.1021/ic034334b. [DOI] [PubMed] [Google Scholar]
- 33.Kaljurand I, Kutt A, Soovali L, Rodima T, Maemets V, Leito I, Koppel IA. J Org Chem. 2005;70:1019. doi: 10.1021/jo048252w. [DOI] [PubMed] [Google Scholar]
- 34.Boyke CA. PhD Thesis. University of Illinois at Urbana-Champaign; 2006. [Google Scholar]
- 35.Bradley DC, Harding IS, Keefe AD, Motevalli M, Zheng DH. J Chem Soc, Dalton Trans. 1996:3931. [Google Scholar]
- 36.Besora M, Lledos A, Maseras F. Chem Soc Rev. 2009;38:957. doi: 10.1039/b608404b. [DOI] [PubMed] [Google Scholar]
- 37.Wang N, Wang M, Zhang TT, Li P, Liu JH, Sun LC. Chem Commun. 2008:5800. doi: 10.1039/b811352a. [DOI] [PubMed] [Google Scholar]
- 38.Eilers G, Schwartz L, Stein M, Zampella G, de Gioia L, Ott S, Lomoth R. Chem—Eur J. 2007;13:7075. doi: 10.1002/chem.200700019. [DOI] [PubMed] [Google Scholar]
- 39.Jablonskytė A, Wright JA, Fairhurst SA, Peck JNT, Ibrahim SK, Oganesyan VS, Pickett CJ. J Am Chem Soc. 2011;133:18606. doi: 10.1021/ja2087536. [DOI] [PubMed] [Google Scholar]
- 40.Berggren G, Adamska A, Lambertz C, Simmons TR, Esselborn J, Atta M, Gambarelli S, Mouesca JM, Reijerse E, Lubitz W, Happe T, Atero V, Fontecave M. Nature. 2013;499:66. doi: 10.1038/nature12239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Greco C, Bruschi M, Fantucci P, Ryde U, De Gioia L. Chem—Eur J. 2011;17:1954. doi: 10.1002/chem.201001493. [DOI] [PubMed] [Google Scholar]
- 42.Mack AE, Rauchfuss TB, Ohnishi K, Ohki Y, Tatsumi K. Inorg Synth. 2010;35:143. [Google Scholar]
- 43.Reynard KE, Sherman RE, Smith HD, Hohnstedt LF, Gassenheimer G, Wartik T. Inorg Synth. 2007:52. [Google Scholar]
- 44.Travis AL, Binding SC, Zaher H, Anold TAQ, Buffet JC, O'Hare D. Dalton Trans. 2013;42:2431. doi: 10.1039/c2dt32525j. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.

